Posts

Elicio pancreatic cancer vaccine misses Phase II primary endpoint but shows post-hoc signal in resected patients

on

Agios Licenses Oscotec Blood Disorder Drug Cevidoplenib in $165M Deal Despite Phase 2 Setback

on

Can Revolution's miracle pancreatic cancer drug be topped? Immuneering, Actuate say yes – BioSpace, Stat News, and clinical trial updates, May 2026

on

Akeso Spotlights AML Data for Anti‑CD47 mAb Ahead of EHA 2026

on

AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Phase II Trial in Parkinson's Disease

on

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

on

Rezatapopt Shows Early Promise in TP53 Y220C-Mutant Tumors in PYNNACLE Phase II Trial

on

Alkermes Pushes Narcolepsy Program to Phase III With Highly Competitive Mid-Stage Data

on

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

on

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

on

Sanofi Challenges Novartis' Dominance with Clinically Meaningful Pancreatic Tumor Data from AlphaMedix Phase II Trial

on

Roche and Alnylam Push Zilebesiran into Phase III Trial Despite Mixed Phase II Hypertension Data

on

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

on

Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced

on

Corcept Highlights Survival Benefit Despite ALS Trial's Missed Primary Endpoint

on

Wave Life Sciences' WVE-N531 Shows Promise in Duchenne Muscular Dystrophy Treatment

on

LB Pharma's Phase II Success Revitalizes Benzamide Antipsychotics for US Schizophrenia Treatment

on

LB Pharma's Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia

on

LB Pharma's Phase II Success Revives Promising Antipsychotic Class for US Patients with Schizophrenia

on

LB Pharma's Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial

on